Skip Navigation

Sapna Syngal, MD, MPH


Make an Appointment


  • Director of Research, Center for Cancer Genetics and Prevention
  • Director, Gastrointestinal Cancer Genetics and Prevention Clinics
  • Director, Gastroenterology, Brigham and Women's Hospital
  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Clinical Interests

  • Cancer screening and prevention
  • Familial cancer syndromes
  • Gastrointestinal cancers

Contact Information

  • Appointments617-632-5577 (new patients)
  • Office Phone Number617-632-2178
  • Fax617-632-4088


Dr. Syngal received her MD from McGill University in 1990 and completed her clinical training in Internal Medicine and Gastroenterology at Brigham and Women's Hospital. She received her MPH from Harvard School of Public Health and completed a research fellowship at the Harvard Education Program in Cancer Prevention. She joined DFCI in 1995.

Board Certification:

  • Gastroenterology, 1997
  • Internal Medicine, 1993


  • Brigham and Women's Hospital, Gastroenterology


  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • McGill University Faculty of Medicine

Recent Awards:

  • Elected as a member to The Amercian Society for Clinical Investigation 2009
  • Partners in Excellence Team Award from Brigham and Women's Hospital 2011
  • Lifetime Achievement Award from The Collaborative Group of the Americas 2012


Genetics, Early Detection, and Prevention of Gastrointestinal Cancers

Basic laboratory research, technology, and the pharmaceutical industry are creating a vast array of new diagnostic tests and potential therapies for cancer. Our research program focuses on studying the effectiveness of these technologies with the goal of providing individuals and their physicians with new cancer-prevention tools that include clarification of personal risk, primary prevention, novel screening techniques, and new chemotherapeutic agents.

One of the main goals of our research group is to evaluate the impact of genetic discoveries as tools for cancer risk assessment. We have designed a web-based risk assessment tool called PREMM which providers can use at no cost to determine the utility of recommending genetic testing for Lynch syndrome.  Currently, we are piloting a self-administered version of this tool to patients in a primary care practice with the aim of promoting a patient-centered approach to the management of hereditary colon cancer syndromes.  We are also working on expanding this clinical prediction model to include other hereditary colon cancer syndromes.

Our group is also interested in evaluating novel genetic and other biomarkers for early cancer detection as well as cancer prevention modalities. As part of the National Cancer Institute's Early Cancer Detection Research Network, we are participating in an ongoing multicenter study evaluating novel serum biomarkers for early colon cancer detection. In addition, we are also part of a multicenter clinical trial evaluating a pharmacological agent that may defer the need for surgical intervention in patients with known Familial Adenomatous Polyposis syndrome.

Since expanding our research to include the genetics and early detection of pancreatic cancer, we have developed the Dana-Farber/Harvard Cancer Center Pancreatic Cancer Genes Study registry, which collects data on family history and epidemiologic risk factors, as well as DNA and tissue samples. We are a funded site for the National Cancer Institute Pancreatic Cancer Genetic Epidemiologic Consortium study, whose mission is to identify susceptibility genes for pancreatic cancer to improve risk assessment and early detection.


Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1124
Boston, MA 02215
Get Directions